At the Annual General Meeting of Novo Nordisk A/S today, the shareholders adopted the following resolutions: * Adoption of the audited Annual Report 2006, including approval of the remuneration of the Board of Directors. * Resolution to distribute the profit according to the adopted Annual Report 2006. The dividend will be DKK 7.00 per share of DKK 2, an increase of 17% compared with 2005. * Re-election of the following current board members elected by the Annual General Meeting: Sten Scheibye, Göran A Ando, Kurt Briner, Henrik Gürtler, Niels Jacobsen, Kurt Anker Nielsen and Jørgen Wedel. * Re-election of the auditor, PricewaterhouseCoopers. * Resolution to reduce the Company's B share capital from DKK 566,432,800 to DKK 539,472,800 by 13,480,000 B shares of DKK 2 each out of the Company's own holdings of B shares at a nominal value of DKK 26,960,000, equal to 4% of the total share capital. After completion of the share capital decrease, the Company's share capital will amount to DKK 646,960,000 divided into A share capital of DKK 107,487,200 and B share capital of DKK 539,472,800. * Authorisation for the Board of Directors, until the next Annual General Meeting, to allow the Company to acquire own shares of up to 10% of the share capital and at the price quoted at the time of the purchase with a deviation of up to 10%, cf Section 48 of the Danish Public Companies Act. The Board of Directors In February 2006, Novo Nordisk employees in Denmark elected four board members: Johnny Henriksen, Anne Marie Kverneland and Stig Strøbæk were re-elected and Søren Thuesen Pedersen was elected. Accordingly the Board of Directors of Novo Nordisk A/S comprises: * Sten Scheibye * Göran A Ando * Kurt Briner * Henrik Gürtler * Johnny Henriksen (employee representative) * Niels Jacobsen * Anne Marie Kverneland (employee representative) * Kurt Anker Nielsen * Søren Thuesen Pedersen (employees representative) * Stig Strøbæk (employee representative) * Jørgen Wedel. For information on the board members, please refer to novonordisk.com. At a board meeting held immediately after the Annual General Meeting, the Board of Directors constituted itself with Sten Scheibye as chairman and Göran A Ando as vice-chairman. The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and Jørgen Wedel as members of the Audit Committee with Kurt Anker Nielsen as chairman. Kurt Anker Nielsen and Niels Jacobsen were designated by the Board of Directors as Audit Committee Financial Experts. Finally, the Board of Directors designated Göran A Ando as Research and Development facilitator. Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. For further information please contact: Media: Investors: Outside North America: Outside North America: Mike Rulis Mads Veggerby Lausten Tel: (+45) 4442 3573 Tel: (+45) 4443 7919 mike@novonordisk.com mlau@novonordisk.com Hans Rommer Tel: (+45) 4442 4765 hrmm@novonordisk.com In North America: In North America: Lori Moore Christian Qvist Frandsen Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937 lrmo@novonordisk.com cqfr@novonordisk.com Stock Exchange Announcement no 7 / 2007